Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial

Christoph Wanner; Mark E. Cooper; Odd Erik Johansen; Robert Toto; Julio Rosenstock; Darren K. McGuire; Steven E. Kahn; Egon Pfarr; Sven Schnaidt; Maximilian von Eynatten; Jyothis T. George; Nicholas D. Gollop; Nikolaus Marx; John H. Alexander; Bernard Zinman; Vlado Perkovic; CARMELINA Invest

doi:10.1093/ckj/sfab104

Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial

Christoph Wanner
, Mark E. Cooper
, Odd Erik Johansen
, Robert Toto
, Julio Rosenstock
, Darren K. McGuire
, Steven E. Kahn
, Egon Pfarr
, Sven Schnaidt
, Maximilian von Eynatten
, Jyothis T. George
, Nicholas D. Gollop
, Nikolaus Marx
, John H. Alexander
, Bernard Zinman
, Vlado Perkovic
, CARMELINA Invest

Norwich Medical School

Research output: Contribution to journal › Article › peer-review

Abstract

This is a correction to: Clinical Kidney Journal, Volume 14, Issue 1, January 2021, Pages 226–236, https://doi.org/10.1093/ckj/sfaa225

In the originally published version of this manuscript, the legend for Figure 4 incorrectly directed the reader to the right side of the curve, this has been corrected to read: ‘Point estimates on the left side of the curve indicate a positive effect for LINA.’

Original language	English
Pages (from-to)	2136
Number of pages	1
Journal	Clinical Kidney Journal
Volume	14
Issue number	9
Early online date	14 Jul 2021
DOIs	https://doi.org/10.1093/ckj/sfab104
Publication status	Published - Sept 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/ckj/sfab104Licence: CC BY-NC

Cite this

Wanner, C., Cooper, M. E., Johansen, O. E., Toto, R., Rosenstock, J., McGuire, D. K., Kahn, S. E., Pfarr, E., Schnaidt, S., von Eynatten, M., George, J. T., Gollop, N. D., Marx, N., Alexander, J. H., Zinman, B., Perkovic, V., & CARMELINA Invest (2021). Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial. Clinical Kidney Journal, 14(9), 2136. https://doi.org/10.1093/ckj/sfab104

@article{d6cfcc1c10e04c13857b09d1d2f7dc17,

title = "Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial",

abstract = "This is a correction to: Clinical Kidney Journal, Volume 14, Issue 1, January 2021, Pages 226{\textendash}236, https://doi.org/10.1093/ckj/sfaa225 In the originally published version of this manuscript, the legend for Figure 4 incorrectly directed the reader to the right side of the curve, this has been corrected to read: {\textquoteleft}Point estimates on the left side of the curve indicate a positive effect for LINA.{\textquoteright}",

author = "Christoph Wanner and Cooper, \{Mark E.\} and Johansen, \{Odd Erik\} and Robert Toto and Julio Rosenstock and McGuire, \{Darren K.\} and Kahn, \{Steven E.\} and Egon Pfarr and Sven Schnaidt and \{von Eynatten\}, Maximilian and George, \{Jyothis T.\} and Gollop, \{Nicholas D.\} and Nikolaus Marx and Alexander, \{John H.\} and Bernard Zinman and Vlado Perkovic and \{CARMELINA Invest\}",

year = "2021",

month = sep,

doi = "10.1093/ckj/sfab104",

language = "English",

volume = "14",

pages = "2136",

journal = "Clinical Kidney Journal",

issn = "2048-8505",

publisher = "Oxford University Press",

number = "9",

}

Wanner, C, Cooper, ME, Johansen, OE, Toto, R, Rosenstock, J, McGuire, DK, Kahn, SE, Pfarr, E, Schnaidt, S, von Eynatten, M, George, JT, Gollop, ND, Marx, N, Alexander, JH, Zinman, B, Perkovic, V & CARMELINA Invest 2021, 'Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial', Clinical Kidney Journal, vol. 14, no. 9, pp. 2136. https://doi.org/10.1093/ckj/sfab104

Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial. / Wanner, Christoph; Cooper, Mark E.; Johansen, Odd Erik et al.
In: Clinical Kidney Journal, Vol. 14, No. 9, 09.2021, p. 2136.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d)

T2 - the carmelina randomised controlled trial

AU - Wanner, Christoph

AU - Cooper, Mark E.

AU - Johansen, Odd Erik

AU - Toto, Robert

AU - Rosenstock, Julio

AU - McGuire, Darren K.

AU - Kahn, Steven E.

AU - Pfarr, Egon

AU - Schnaidt, Sven

AU - von Eynatten, Maximilian

AU - George, Jyothis T.

AU - Gollop, Nicholas D.

AU - Marx, Nikolaus

AU - Alexander, John H.

AU - Zinman, Bernard

AU - Perkovic, Vlado

AU - CARMELINA Invest

PY - 2021/9

Y1 - 2021/9

N2 - This is a correction to: Clinical Kidney Journal, Volume 14, Issue 1, January 2021, Pages 226–236, https://doi.org/10.1093/ckj/sfaa225 In the originally published version of this manuscript, the legend for Figure 4 incorrectly directed the reader to the right side of the curve, this has been corrected to read: ‘Point estimates on the left side of the curve indicate a positive effect for LINA.’

AB - This is a correction to: Clinical Kidney Journal, Volume 14, Issue 1, January 2021, Pages 226–236, https://doi.org/10.1093/ckj/sfaa225 In the originally published version of this manuscript, the legend for Figure 4 incorrectly directed the reader to the right side of the curve, this has been corrected to read: ‘Point estimates on the left side of the curve indicate a positive effect for LINA.’

UR - https://www.scopus.com/pages/publications/85143252777

U2 - 10.1093/ckj/sfab104

DO - 10.1093/ckj/sfab104

M3 - Article

SN - 2048-8505

VL - 14

SP - 2136

JO - Clinical Kidney Journal

JF - Clinical Kidney Journal

IS - 9

ER -

Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial

Abstract

UN SDGs

Access to Document

Other files and links

Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial

Cite this